News | 03.29.20
POPular-TAVI Trial Evaluates Risk of Antiplatelet Drugs for TAVR Patients With Atrial Fibrillation
March 29, 2020—Patients with atrial fibrillation who took oral anticoagulants alone after undergoing transcatheter aortic valve replacement (TAVR) had a lower rate of bleeding complications without an increased risk of clotting-related complications compared to patients who took antiplatelet medication in addition to oral anticoagulants in the POPular-TAVI trial presented by Vincent Nijenhuis, MD, at the virtual American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).
News | 03.28.20
Combined Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease Studied in the COMPASS Trial
March 28, 2020—Findings from a prespecified analysis of COMPASS trial on the role of combination antiplatelet and anticoagulation therapy in diabetes and cardiovascular disease were presented by Deepak L. Bhatt, MD, in the virtual conference of the American College of Cardiology’s Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC).
News | 03.28.20
TAILOR-PCI Trial Evaluates Genetic Testing to Guide Post-PCI Antiplatelet Therapy
March 28, 2020—The American College of Cardiology (ACC) announced that findings from the TAILOR-PCI international clinical trial to test the effectiveness of genetic testing to guide which antiplatelet medication was given to patients after percutaneous coronary intervention (PCI)—were presented by coprincipal investigator Naveen L. Pereira, MD, at the ACC's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC), which is being held this year as a virtual conference.
News | 03.28.20
VOYAGER PAD Evaluates Risk of Adverse Events With Rivaroxaban in Symptomatic PAD After Revascularization
March 28, 2020—At the American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC) held this year as a virtual conference, Marc P. Bonaca, MD, presented findings from the VOYAGER PAD study demonstrating that patients with symptomatic peripheral artery disease (PAD) who took rivaroxaban with aspirin after undergoing lower extremity revascularization had a 15% reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.
News | 12.12.19
Medicure Completes Enrollment in FABOLUS-FASTER Trial of Aggrastat in Patients Undergoing PCI
December 12, 2019—Medicure Inc. announced the completion of the FABOLUS-FASTER phase 4 trial of Aggrastat (tirofiban hydrochloride) injection versus Kengreal (cangrelor; The Medicines Company) in patients undergoing percutaneous coronary intervention (PCI).
News | 12.05.19
FDA Approves Enoxaparin Sodium Injection in the United States
December 5, 2019—Meitheal Pharmaceuticals, a generic injectable pharmaceuticals company based in Chicago, Illinois, announced that the FDA has approved the company's enoxaparin sodium injection exclusively through its partnership with Nanjing King-friend Biochemical Pharmaceutical Co., Ltd., its majority shareholder.
News | 11.19.19
ISCHEMIA Provides Clarity on Invasive Strategies Versus Medical Therapy to Manage Higher-Risk Patients With Stable Ischemic Heart Disease
November 16, 2019—At the American Heart Association (AHA) scientific sessions 2019, held November 16–18 in Philadelphia, Pennsylvania, Judith S. Hochman, MD, presented findings from the ISCHEMIA trial, which sought to determine the best management strategy for higher-risk patients with stable ischemic heart disease and moderate to severe ischemia on stress testing. John A. Spertus, MD, then presented the quality-of-life (QOL) findings from the ISCHEMIA trial.
News | 10.21.19
FDA Approves AstraZeneca's Farxiga for Patients With Type 2 Diabetes
October 21, 2019—AstraZeneca announced that the FDA has approved Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
News | 10.17.19
NICE Publishes Guidance on Rivaroxaban for Preventing Atherothrombotic Events in Patients With CAD or PAD
October 17, 2019—The United Kingdom’s National Institute for Health and Care Excellence (NICE) has published its technology appraisal guidance (TA607) on evidence-based recommendations on rivaroxaban (Xarelto; Bayer AG, marketed in the United States by the Janssen Pharmaceutical Companies of Johnson & Johnson) for preventing atherothrombotic events in adults with coronary artery disease (CAD) or peripheral artery disease (PAD).
News | 10.17.19
Ticagrelor Monotherapy Shows Promise for Patients Undergoing Multivessel PCI in GLOBAL LEADERS Study
October 17, 2019—Data from the GLOBAL LEADERS study suggest that long-term ticagrelor monotherapy after 1-month dual antiplatelet therapy (DAPT) can favorably balance ischemic and bleeding risks in patients undergoing multivessel percutaneous coronary intervention (PCI).
News | 10.15.19
Study Evaluates Preprocedural Anticoagulation for Patients With STEMI Undergoing Primary PCI
October 15, 2019—Online in Catheterization and Cardiovascular Interventions, Warren J. Cantor, MD, et al published findings from an evaluation of upstream anticoagulation for patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The investigators sought to assess the relationship between preprocedural anticoagulation use and clinical and angiographic outcomes.
News | 10.14.19
FDA Approves Xarelto for VTE Prevention in Acutely Ill Medical Patients
October 14, 2019—The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the FDA has approved Xarelto (rivaroxaban) for the prevention of venous thromboembolism (VTE) in hospitalized acutely ill medical patients at risk for thromboembolic complications who are not at high risk of bleeding.
News | 09.27.19
TWILIGHT Study Supports Ticagrelor Monotherapy at 3 Months After PCI and DAPT
September 26, 2019—The Cardiovascular Research Foundation (CRF) announced that results from the TWILIGHT study were presented by investigator Roxana Mehran, MD, at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 25–29 in San Francisco, California.
News | 09.27.19
Onyx ONE Study Evaluates 1-Month DAPT in High-Bleeding Risk Patients
September 26, 2019—The Cardiovascular Research Foundation (CRF) announced that results from the Onyx One study were presented by Stephan Windecker, MD, at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 25–29 in San Francisco, California.
News | 09.26.19
EVOLVE Short DAPT Study Shows Low Rate of Adverse Events in High-Bleeding Risk Patients
September 26, 2019—The Cardiovascular Research Foundation (CRF) announced that results from the EVOLVE Short DAPT study were presented by lead investigator Ajay J. Kirtane, MD, at TCT 2019, the 31st annual Transcatheter Cardiovascular Therapeutics scientific symposium, which is sponsored by CRF and held September 25–29 in San Francisco, California.
News | 09.09.19
Recardio Begins Phase 2 Trial of Dutogliptin in Early Recovery Postmyocardial Infarction
September 9, 2019—Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that its phase 2 study of dutogliptin in combination with filgrastim in early recovery postmyocardial infarction is now enrolling and recruiting in multiple European and United States centers.